2024
Characterization of time toxicity in older patients with metastatic breast cancer
Atre S, Soulos P, Kuderer N, Gross C, Baum L, Dinan M, Lustberg M. Characterization of time toxicity in older patients with metastatic breast cancer. Breast Cancer Research And Treatment 2024, 207: 541-550. PMID: 38816556, DOI: 10.1007/s10549-024-07379-7.Peer-Reviewed Original ResearchMetastatic breast cancerBone-modifying agentsComorbid medical conditionsOlder patientsBreast cancerRetrospective cohort studySEER-Medicare databaseTreatment typeCancer treatment modalityTreatment modalitiesSEER-MedicareCohort studyUnadjusted analysisPatientsAge-related impactCancer treatmentComorbiditiesDay patientsCancerRadiotherapyOlder ageMedical conditionsToxicityTreatmentSociodemographic factors
2023
Trends in new and persistent opioid use in older adults with and without cancer
Baum L, KC M, Soulos P, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Trends in new and persistent opioid use in older adults with and without cancer. Journal Of The National Cancer Institute 2023, 116: 316-323. PMID: 37802882, DOI: 10.1093/jnci/djad206.Peer-Reviewed Original ResearchAdditional opioid useNew opioid useOpioid useNon-metastatic cancerPersistent opioid useRetrospective cohort studySolid tumor malignanciesClinical strataEligible patientsNaïve patientsOpioid prescribingMetastatic patientsSurgery patientsCohort studySEER-MedicareMetastatic cancerPatientsTumor malignancyCancerOlder adultsSurgeryRandom sampleAdditional useChemotherapyPrescribing
2022
End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy
Dzimitrowicz H, Wilson L, Jackson B, Spees L, Baggett C, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M, Wheeler S. End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy. JCO Oncology Practice 2022, 19: e213-e227. PMID: 36413741, PMCID: PMC9970274, DOI: 10.1200/op.22.00401.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaOral anticancer agentsDays of lifeRenal cell carcinomaEOL careSystemic therapySEER-MedicareHospital deathCell carcinomaLife careIntensive care unit admissionCancer informationAggressive EOL careHigh-quality EOLOral anticancer therapySystemic therapy useCare unit admissionMultivariable logistic regressionQuality of endUnit admissionED visitsOlder patientsYounger patientsHospital admissionTherapy useFactors associated with the quality of end-of-life care for patients with metastatic renal cell carcinoma.
Dzimitrowicz H, Wilson L, Jackson B, Spees L, Baggett C, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M, Wheeler S. Factors associated with the quality of end-of-life care for patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2022, 40: 300-300. DOI: 10.1200/jco.2022.40.6_suppl.300.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anti-cancer agentsRenal cell carcinomaSEER-MedicareDays of lifeSystemic therapyICU admissionCell carcinomaOdds ratioLife careSEER-Medicare cohortSystemic therapy useMultivariable logistic regressionUse of hospiceQuality of endHigh-quality endMRCC diagnosisAnti-cancer agentsMost patientsOlder patientsHospital admissionMedian ageTherapy useImmunotherapy treatmentRetrospective study
2021
Vitamin D, Insulin-Like Growth Factor, and Cognitive Performance: Age and Sex Variations
Miller S, Wilson L, Greiner M, Pritchard J, Zhang T, Kaye D, Cohen H, Dinan M. Vitamin D, Insulin-Like Growth Factor, and Cognitive Performance: Age and Sex Variations. Innovation In Aging 2021, 5: 703-703. PMCID: PMC8969788, DOI: 10.1093/geroni/igab046.2613.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaRenal cell carcinomaProportional hazards regressionOral anticancer agentsMRCC diagnosisCell carcinomaHazards regressionRisk factorsCox proportional hazards regressionOlder adultsNon-cancer controlsMild cognitive impairmentCohort entryRenal dysfunctionOnly patientsSurgical therapyWhite patientsBlack patientsSEER-MedicareDementia onsetMAIN OUTCOMEExclusion criteriaHigh riskPatientsCognitive impairment
2019
Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer
Rotter J, Wilson L, Greiner MA, Pollack CE, Dinan M. Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer. Breast Cancer Research And Treatment 2019, 176: 445-451. PMID: 31028607, PMCID: PMC6556129, DOI: 10.1007/s10549-019-05248-2.Peer-Reviewed Original ResearchConceptsPatient-level analysisOncotype DXBreast cancerMedical oncologistsEarly-stage breast cancerGenomic testingPhysician networksODX testingMore patientsRetrospective studySEER-MedicareStudy criteriaSuboptimal treatmentCancer patientsMedian numberModifiable driversModifiable meansPatientsOncologistsLogistic mixed modelsEarly adoption periodWomenCancerPhysiciansGenomic assays